Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
01:35pm, Wednesday, 06'th Mar 2024
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
11:11am, Tuesday, 05'th Mar 2024
Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.
SAN FRANCISCO , March 5, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiatio
Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript
10:54pm, Monday, 04'th Mar 2024
Nektar Therapeutics (NASDAQ:NKTR ) Q4 2023 Earnings Conference Call March 4, 2024 5:00 PM ET Company Participants Vivian Wu - Director, Investor Relations and Corporate Affairs Howard Robin - Presiden
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
06:31pm, Monday, 04'th Mar 2024
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.32 per share a year ago.
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
04:15pm, Monday, 04'th Mar 2024
SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023. Cash and investments in
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
08:30am, Monday, 04'th Mar 2024
SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced that it has e
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference
06:00pm, Tuesday, 27'th Feb 2024
SAN FRANCISCO , Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, Ma
SAN FRANCISCO , Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, a
Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know
11:06am, Tuesday, 20'th Feb 2024
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
06:00pm, Wednesday, 03'rd Jan 2024
SAN FRANCISCO , Jan. 3, 2024 /PRNewswire/ -- Nektar (Nasdaq: NKTR) management is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Janua
– NKTR-255 Combination Expanded NK Cells and Enhanced ADCC Against Rituximab-Resistant Burkitt Lymphoma (BL) Cells – SAN FRANCISCO , Dec. 11, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKT
Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue?
12:47pm, Thursday, 07'th Dec 2023
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss
01:31pm, Wednesday, 08'th Nov 2023
Nektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line.
Nektar Therapeutics (NKTR) Q3 2023 Earnings Call Transcript
09:11pm, Tuesday, 07'th Nov 2023
Nektar Therapeutics (NASDAQ:NKTR ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Vivian Wu - Director, IR and Corporate Affairs Howard Robin - President and CEO Jon
